Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 548913, 11 pages
http://dx.doi.org/10.4061/2010/548913
Review Article

Brain Imaging of Nicotinic Receptors in Alzheimer's Disease

Division of Clinical Neuroscience, Center for Forensic Mental Health, Chiba University, 1-8-1 Inohana Chiba 260-8670, Japan

Received 30 October 2010; Accepted 8 December 2010

Academic Editor: Adam S. Fleisher

Copyright © 2010 Jin Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Evans, H. H. Funkenstein, M. S. Albert et al., “Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported,” Journal of the American Medical Association, vol. 262, no. 18, pp. 2551–2556, 1989. View at Google Scholar · View at Scopus
  2. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M. Arrighi, “Forecasting the global burden of Alzheimer's disease,” Alzheimer's and Dementia, vol. 3, no. 3, pp. 186–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. N. Octave, “The amyloid peptide and its precursor in Alzheimer's disease,” Reviews in the Neurosciences, vol. 6, no. 4, pp. 287–316, 1995. View at Google Scholar · View at Scopus
  4. E. Grober, C. B. Hall, R. B. Lipton, A. B. Zonderman, S. M. Resnick, and C. Kawas, “Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease,” Journal of the International Neuropsychological Society, vol. 14, no. 2, pp. 266–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C. M. van Duijn and A. Hofman, “Relation between nicotine intake and Alzheimer's disease,” British Medical Journal, vol. 302, no. 6791, pp. 1491–1494, 1991. View at Google Scholar · View at Scopus
  6. A. B. Graves, C. M. van Duijn, V. Chandra et al., “Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies,” International Journal of Epidemiology, vol. 20, supplement 2, pp. S48–S57, 1991. View at Google Scholar
  7. J. M. Rusted and S. Trawley, “Comparable effects of nicotine in smokers and nonsmokers on a prospective memory task,” Neuropsychopharmacology, vol. 31, no. 7, pp. 1545–1549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. G. E. Swan and C. N. Lessov-Schlaggar, “The effects of tobacco smoke and nicotine on cognition and the brain,” Neuropsychology Review, vol. 17, no. 3, pp. 259–273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Peters, R. Poulter, J. Warner, N. Beckett, L. Burch, and C. Bulpitt, “Smoking, dementia and cognitive decline in the elderly, a systematic review,” BMC Geriatrics, vol. 8, article 36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. K. Cataldo, J. J. Prochaska, and S. A. Glantz, “Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation,” Journal of Alzheimer's Disease, vol. 19, no. 2, pp. 465–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. K. Cataldo and S. A. Glantz, “Smoking cessation and Alzheimer's disease: facts, fallacies and promise,” Expert Review of Neurotherapeutics, vol. 10, no. 5, pp. 629–631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Gotti, M. Zoli, and F. Clementi, “Brain nicotinic acetylcholine receptors: native subtypes and their relevance,” Trends in Pharmacological Sciences, vol. 27, no. 9, pp. 482–491, 2006. View at Publisher · View at Google Scholar
  13. D. Paterson and A. Nordberg, “Neuronal nicotinic receptors in the human brain,” Progress in Neurobiology, vol. 61, no. 1, pp. 75–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Dani and D. Bertrand, “Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 699–729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Z. Guan, X. Zhang, R. Ravid, and A. Nordberg, “Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease,” Journal of Neurochemistry, vol. 74, no. 1, pp. 237–243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. X. A. Perez, T. Bordia, J. M. McIntosh, and M. Quik, “α6β2* and α4β2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease,” Molecular Pharmacology, vol. 78, no. 5, pp. 971–980, 2010. View at Publisher · View at Google Scholar
  17. E. K. Perry, C. M. Morris, J. A. Court et al., “Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology,” Neuroscience, vol. 64, no. 2, pp. 385–395, 1995. View at Publisher · View at Google Scholar
  18. E. Hellström-Lindahl, M. Mousavi, X. Zhang, R. Ravid, and A. Nordberg, “Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain,” Molecular Brain Research, vol. 66, no. 1-2, pp. 94–103, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Burghaus, U. Schütz, U. Krempel et al., “Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients,” Molecular Brain Research, vol. 76, no. 2, pp. 385–388, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Yankner, L. K. Duffy, and D. A. Kirschner, “Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides,” Science, vol. 250, no. 4978, pp. 279–282, 1990. View at Google Scholar · View at Scopus
  21. N. W. Kowall, M. F. Beal, J. Busciglio, L. K. Duffy, and B. A. Yankner, “An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 16, pp. 7247–7251, 1991. View at Google Scholar · View at Scopus
  22. T. Kihara, S. Shimohama, M. Urushitani et al., “Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β- amyloid toxicity,” Brain Research, vol. 792, no. 2, pp. 331–334, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Fu and J. H. Jhamandas, “β-amyloid peptide activates non-α7 nicotinic acetylcholine receptors in rat basal forebrain neurons,” Journal of Neurophysiology, vol. 90, no. 5, pp. 3130–3136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. N. Wu, Y. X. He, F. Guo, and J. S. Qi, “α4β2 nicotinic acetylcholine receptors are required for the amyloid β protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo,” Brain Research Bulletin, vol. 77, no. 2-3, pp. 84–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. A. Newhouse, A. Potter, and A. Singh, “Effects of nicotinic stimulation on cognitive performance,” Current Opinion in Pharmacology, vol. 4, no. 1, pp. 36–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Loughead, R. Ray, E. P. Wileyto et al., “Effects of the α4β2 partial agonist varenicline on brain activity and working memory in abstinent smokers,” Biological Psychiatry, vol. 67, no. 8, pp. 715–721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. D. Flynn and D. C. Mash, “Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal,” Journal of Neurochemistry, vol. 47, no. 6, pp. 1948–1954, 1986. View at Google Scholar · View at Scopus
  28. P. J. Whitehouse, A. M. Martino, P. G. Antuono et al., “Nicotinic acetylcholine binding sites in Alzheimer's disease,” Brain Research, vol. 371, no. 1, pp. 146–151, 1986. View at Google Scholar
  29. P. J. Whitehouse, A. M. Martino, M. V. Wagster et al., “Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study,” Neurology, vol. 38, no. 5, pp. 720–723, 1988. View at Google Scholar · View at Scopus
  30. U. Warpman and A. Nordberg, “Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains,” NeuroReport, vol. 6, no. 17, pp. 2419–2423, 1995. View at Google Scholar · View at Scopus
  31. A. Marutle, U. Warpman, N. Bogdanovic, L. Lannfelt, and A. Nordberg, “Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation,” Journal of Neurochemistry, vol. 72, no. 3, pp. 1161–1169, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Wevers, L. Burghaus, N. Moser et al., “Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches,” Behavioural Brain Research, vol. 113, no. 1-2, pp. 207–215, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. J. D. Gallezot, M. Bottlaender, M. C. Grégoire et al., “in vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET,” Journal of Nuclear Medicine, vol. 46, no. 2, pp. 240–247, 2005. View at Google Scholar · View at Scopus
  34. A. L. Brody, M. A. Mandelkern, E. D. London et al., “Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors,” Archives of General Psychiatry, vol. 63, no. 8, pp. 907–915, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Kadir, O. Almkvist, A. Wall, B. Långström, and A. Nordberg, “PET imaging of cortical C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease,” Psychopharmacology, vol. 188, no. 4, pp. 509–520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Maziere, D. Comar, C. Marazano, and G. Berger, “Nicotine 11C: synthesis and distribution kinetics in animals,” European Journal of Nuclear Medicine, vol. 1, no. 4, pp. 255–258, 1976. View at Google Scholar · View at Scopus
  37. C. Halldin, K. Nagren, C. G. Swahn, B. Langstrom, and H. Nyback, “(S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET,” International Journal of Radiation Applications and Instrumentation B, vol. 19, no. 8, pp. 871–880, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Nyback, A. Nordberg, B. Langstrom et al., “Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography,” Progress in Brain Research, vol. 79, pp. 313–319, 1989. View at Google Scholar · View at Scopus
  39. A. Nordberg, L. Nilsson-Hakansson, A. Adem et al., “The role of nicotinic receptors in the pathophysiology of Alzheimer's disease,” Progress in Brain Research, vol. 79, pp. 353–362, 1989. View at Google Scholar · View at Scopus
  40. A. Nordberg, H. Lundqvist, P. Hartvig, A. Lilja, and B. Langstrom, “Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains—in vivo assessment using positron emission tomography,” Alzheimer Disease and Associated Disorders, vol. 9, no. 1, pp. 21–27, 1995. View at Google Scholar · View at Scopus
  41. A. Kadir, T. Darreh-Shori, O. Almkvist et al., “PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD,” Neurobiology of Aging, vol. 29, no. 8, pp. 1204–1217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Nordberg, H. Lundqvist, P. Hartvig et al., “Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment,” Dementia and Geriatric Cognitive Disorders, vol. 8, no. 2, pp. 78–84, 1997. View at Google Scholar
  43. F. Grunwald, H. J. Biersack, W. Kuschinsky, D. Sorger, I. Kampfer, and W. H. Knapp, “Nicotine receptor mapping,” European Journal of Nuclear Medicine, vol. 23, no. 8, pp. 1012–1014, 1996. View at Google Scholar · View at Scopus
  44. J. P. Sullivan, D. Donnelly-Roberts, C. A. Briggs et al., “A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand,” Neuropharmacology, vol. 35, no. 6, pp. 725–734, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. L. E. Rueter, M. D. Meyer, and M. W. Decker, “Spinal mechanisms underlying A-85380-induced effects on acute thermal pain,” Brain Research, vol. 872, no. 1-2, pp. 93–101, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. Buckley, C. Surowy, M. Meyer, and P. Curzon, “Mechanism of action of A-85380 in an animal model of depression,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 28, no. 4, pp. 723–730, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. L. E. Rueter, D. L. Donnelly-Roberts, P. Curzon, C. A. Briggs, D. J. Anderson, and R. S. Bitner, “A-85380: a pharmacological probe for the preclinical and clinical investigation of the αβ neuronal nicotinic acetylcholine receptor,” CNS Drug Reviews, vol. 12, no. 2, pp. 100–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. A. G. Mukhin, D. Gündisch, A. G. Horti et al., “5-iodo-a-85380, an α4β2 subtype-selective ligand for nicotinic acetylcholine receptors,” Molecular Pharmacology, vol. 57, no. 3, pp. 642–649, 2000. View at Google Scholar · View at Scopus
  49. S. I. Chefer, E. D. London, A. O. Koren et al., “Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain,” Synapse, vol. 48, no. 1, pp. 25–34, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. S. Kimes, A. G. Horti, E. D. London et al., “2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans,” FASEB Journal, vol. 17, no. 10, pp. 1331–1333, 2003. View at Google Scholar · View at Scopus
  51. J. R. Ellis, V. L. Villemagne, P. J. Nathan et al., “Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study,” Neurobiology of Learning and Memory, vol. 90, no. 2, pp. 404–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Fujita, M. Ichise, C. H. van Dyck et al., “Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 12, pp. 1620–1629, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. E. M. Mitsis, K. P. Cosgrove, J. K. Staley et al., “Age-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT,” Neurobiology of Aging, vol. 30, no. 9, pp. 1490–1497, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. K. P. Cosgrove, J. Batis, F. Bois et al., “β2-nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking,” Archives of General Psychiatry, vol. 66, no. 6, pp. 666–676, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. L. Brody, M. A. Mandelkern, M. R. Costello et al., “Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette,” International Journal of Neuropsychopharmacology, vol. 12, no. 3, pp. 305–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. O. Sabri, K. Kendziorra, H. Wolf, H. J. Gertz, and P. Brust, “Acetylcholine receptors in dementia and mild cognitive impairment,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. S30–S45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Kendziorra, H. Wolf, P. M. Meyer et al., “Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography,” European Journal of Nuclear Medicine and Molecular Imaging. In press. View at Publisher · View at Google Scholar
  58. E. M. Mitsis, K. M. Reech, F. Bois et al., “123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment,” Journal of Nuclear Medicine, vol. 50, no. 9, pp. 1455–1463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. T. O'Brien, S. J. Colloby, S. Pakrasi et al., “α4β2 nicotinic receptor status in Alzheimer's disease using I-5IA-85380 single-photon-emission computed tomography,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 4, pp. 356–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. S. J. Colloby, E. K. Perry, S. Pakrasi et al., “Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in alzheimer's disease and dementia with lewy Bodies,” American Journal of Geriatric Psychiatry, vol. 18, no. 1, pp. 86–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. R. Ellis, P. J. Nathan, V. L. Villemagne et al., “Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]Fluoro-A- 85380 PET,” Psychopharmacology, vol. 202, no. 1–3, pp. 79–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. P. B. S. Clarke, “The fall and rise of neuronal α-bungarotoxin binding proteins,” Trends in Pharmacological Sciences, vol. 13, no. 11, pp. 407–413, 1992. View at Publisher · View at Google Scholar · View at Scopus
  63. H. Y. Wang, D. H. S. Lee, M. R. D'Andrea, P. A. Peterson, R. P. Shank, and A. B. Reitz, “β-Amyloid(1–42) binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology,” Journal of Biological Chemistry, vol. 275, no. 8, pp. 5626–5632, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Y. Wang, D. H. S. Lee, C. B. Davis, and R. P. Shank, “Amyloid peptide Aβ(1–42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors,” Journal of Neurochemistry, vol. 75, no. 3, pp. 1155–1161, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. M. R. D'Andrea, R. G. Nagele, H. Y. Wang, P. A. Peterson, and D. H. S. Lee, “Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease,” Histopathology, vol. 38, no. 2, pp. 120–134, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Dziewczapolski, C. M. Glogowski, E. Masliah, and S. F. Heinemann, “Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 29, no. 27, pp. 8805–8815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Bencherif and P. M. Lippiello, “α7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?” Medical Hypotheses, vol. 74, no. 2, pp. 281–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Bencherif, “Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance,” Acta Pharmacologica Sinica, vol. 30, no. 6, pp. 702–714, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Eddins, R. C. Klein, J. L. Yakel, and E. D. Levin, “Hippocampal infusions of apolipoprotein E peptides induce long-lasting cognitive impairment,” Brain Research Bulletin, vol. 79, no. 2, pp. 111–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. S. Bitner, A. L. Nikkel, S. Markosyan, S. Otte, P. Puttfarcken, and M. Gopalakrishnan, “Selective α7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3β and decreases tau phosphorylation in vivo,” Brain Research, vol. 1265, no. C, pp. 65–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. G. G. Farías, A. S. Vallés, M. Colombres et al., “Wnt-7a induces presynaptic colocalization of α7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons,” Journal of Neuroscience, vol. 27, no. 20, pp. 5313–5325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Oddo, A. Caccamo, J. D. Shepherd et al., “Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Oddo, A. Caccamo, K. N. Green et al., “Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 3046–3051, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. L. M. Billings, S. Oddo, K. N. Green, J. L. McGaugh, and F. M. LaFerla, “Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice,” Neuron, vol. 45, no. 5, pp. 675–688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Nordberg, E. Hellström-Lindahl, M. Lee et al., “Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw),” Journal of Neurochemistry, vol. 81, no. 3, pp. 655–658, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Unger, M. M. Svedberg, W. F. Yu, M. M. Hedberg, and A. Nordberg, “Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 1, pp. 30–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. R. P. Brendza, B. J. Bacskai, J. R. Cirrito et al., “Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 428–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Orr-Urtreger, F. M. Goldner, M. Saeki et al., “Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack α-bungarotoxin binding sites and hippocampal fast nicotinic currents,” Journal of Neuroscience, vol. 17, no. 23, pp. 9165–9171, 1997. View at Google Scholar · View at Scopus
  79. R. Paylor, M. Nguyen, J. N. Crawley, J. Patrick, A. Beaudet, and A. Orr-Urtreger, “α7 nicotinic receptor subunits are not necessary for hippocampal- dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice,” Learning and Memory, vol. 5, no. 4-5, pp. 302–316, 1998. View at Google Scholar · View at Scopus
  80. E. Hoyle, R. F. Genn, C. Fernandes, and I. P. Stolerman, “Impaired performance of α7 nicotinic receptor knockout mice in the five-choice serial reaction time task,” Psychopharmacology, vol. 189, no. 2, pp. 211–223, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. J. W. Young, N. Crawford, J. S. Kelly et al., “Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice,” European Neuropsychopharmacology, vol. 17, no. 2, pp. 145–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Fernandes, E. Hoyle, E. Dempster, L. C. Schalkwyk, and D. A. Collier, “Performance deficit of α7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory,” Genes, Brain and Behavior, vol. 5, no. 6, pp. 433–440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. J. J. Keller, A. B. Keller, B. J. Bowers, and J. M. Wehner, “Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke task,” Behavioural Brain Research, vol. 162, no. 1, pp. 143–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. C. M. Hernandez, R. Kayed, H. Zheng, J. D. Sweatt, and K. T. Dineley, “Loss of α7 nicotinic receptors enhances β-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 30, no. 7, pp. 2442–2453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. K. Hashimoto, Y. Fujita, T. Ishima, H. Hagiwara, and M. Iyo, “Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors,” European Journal of Pharmacology, vol. 553, no. 1–3, pp. 191–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. F. G. Boess, J. de Vry, C. Erb et al., “The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 2, pp. 716–725, 2007. View at Publisher · View at Google Scholar
  87. M. van Kampen, K. Selbach, R. Schneider, E. Schiegel, F. Boess, and R. Schreiber, “AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors,” Psychopharmacology, vol. 172, no. 4, pp. 375–383, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Pichat, O. E. Bergis, J. P. Terranova et al., “SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia,” Neuropsychopharmacology, vol. 32, no. 1, pp. 17–34, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Hashimoto, S. Nishiyama, H. Ohba et al., “[11C]CHIBA-1001 as a novel PET ligand for α7 nicotinic receptors in the brain: a PET study in conscious monkeys,” PLoS ONE, vol. 3, no. 9, article e3231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. K. R. Tietje, D. J. Anderson, R. S. Bitner et al., “Preclinical characterization of A-582941: a novel α7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties,” CNS Neuroscience and Therapeutics, vol. 14, no. 1, pp. 65–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Roncarati, C. Scali, T. A. Comery et al., “Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders,” Journal of Pharmacology and Experimental Therapeutics, vol. 329, no. 2, pp. 459–468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. C. A. Briggs, D. J. Anderson, J. D. Brioni et al., “Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo,” Pharmacology Biochemistry and Behavior, vol. 57, no. 1-2, pp. 231–241, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. J. J. Buccafusco, A. V. Terry Jr., M. W. Decker, and M. Gopalakrishnan, “Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys,” Biochemical Pharmacology, vol. 74, no. 8, pp. 1202–1211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. Q. Liu, J. Zhang, H. Zhu, C. Qin, Q. Chen, and B. Zhao, “Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model,” FASEB Journal, vol. 21, no. 1, pp. 61–73, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Chen, H. Wang, Z. Zhang et al., “DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid25-35-injected mice through preventing the dysfunction of α7 nicotinic receptor,” Journal of Neuroscience Research, vol. 88, no. 8, pp. 1784–1794, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Y. Wang, K. Bakshi, C. Shen, M. Frankfurt, C. Trocmé-Thibierge, and P. Morain, “S 24795 limits β-amyloid-α7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies,” Biological Psychiatry, vol. 67, no. 6, pp. 522–530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Hashimoto and M. Iyo, “Amyloid cascade hypothesis of Alzheimer's disease and α7 nicotinic receptor,” Nihon Shinkei Seishin Yakurigaku Zasshi, vol. 22, no. 2, pp. 9–53, 2002. View at Google Scholar
  98. J. Toyohara and K. Hashimoto, “α7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease,” Open Medicinal Chemistry Journal, vol. 4, pp. 37–56, 2010. View at Google Scholar
  99. A. Nordberg, “Human nicotinic receptors—their role in aging and dementia,” Neurochemistry International, vol. 25, no. 1, pp. 93–97, 1994. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Nordberg, “Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications,” Biological Psychiatry, vol. 49, no. 3, pp. 200–210, 2001. View at Publisher · View at Google Scholar · View at Scopus
  101. P. J. Whitehouse and R. N. Kalaria, “Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications,” Alzheimer Disease and Associated Disorders, vol. 9, supplement 2, pp. 3–5, 1995. View at Google Scholar
  102. C. M. Martin-Ruiz, J. A. Court, E. Molnar et al., “α4 but not α3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease,” Journal of Neurochemistry, vol. 73, no. 4, pp. 1635–1640, 1999. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Davies and S. Feisullin, “Postmortem stability of α-bungarotoxin binding sites in mouse and human brain,” Brain Research, vol. 216, no. 2, pp. 449–454, 1981. View at Publisher · View at Google Scholar · View at Scopus
  104. E. Engidawork, T. Gulesserian, N. Balic, N. Cairns, and G. Lubec, “Changes in nicotinic acetylcholine receptor subunits expression in brain of patients with Down syndrome and Alzheimer's disease,” Journal of Neural Transmission, Supplement, no. 61, pp. 211–222, 2001. View at Google Scholar
  105. L. Falk, A. Nordberg, A. Seiger, A. Kjaeldgaard, and E. Hellström-Lindahl, “Higher expression of α7 nicotinic acetylcholine receptors in human fetal compared to adult brain,” Developmental Brain Research, vol. 142, no. 2, pp. 151–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Marutle, X. Zhang, J. Court et al., “Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia,” Journal of Chemical Neuroanatomy, vol. 22, no. 1-2, pp. 115–126, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. J. A. Court, E. K. Perry, D. Spurden et al., “The role of the cholinergic system in the development of the human cerebellum,” Developmental Brain Research, vol. 90, no. 1-2, pp. 159–167, 1995. View at Publisher · View at Google Scholar
  108. J. Court, C. Martin-Ruiz, M. Piggott, D. Spurden, M. Griffiths, and E. Perry, “Nicotinic receptor abnormalities in Alzheimer's disease,” Biological Psychiatry, vol. 49, no. 3, pp. 175–184, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. R. W. James, N. A. Bersinger, B. Schwendimann, and B. W. Fulpius, “Characterization of iodinated derivatives of α-bungarotoxin,” Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, vol. 361, no. 10, pp. 1517–1524, 1980. View at Google Scholar · View at Scopus
  110. A. R. L. Davies, D. J. Hardick, I. S. Blagbrough, B. V. L. Potter, A. J. Wolstenholme, and S. Wonnacott, “Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors,” Neuropharmacology, vol. 38, no. 5, pp. 679–690, 1999. View at Publisher · View at Google Scholar · View at Scopus
  111. H. A. Navarro, D. Zhong, P. Abraham, H. Xu, and F. I. Carroll, “Synthesis and pharmacological characterization of [125I]iodomethyllycaconitine ([125I]iodo-MLA). A new ligand for the α(7) nicotinic acetylcholine receptor,” Journal of Medicinal Chemistry, vol. 43, no. 2, pp. 142–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. J. Toyohara, J. Wu, and K. Hashimoto, “Recent development of radioligands for imaging α7 nicotinic acetylcholine receptors in the brain,” Current Topics in Medicinal Chemistry, vol. 10, no. 15, pp. 1544–1557, 2010. View at Google Scholar
  113. Y. Tanibuchi, J. Wu, J. Toyohara, Y. Fujita, M. Iyo, and K. Hashimoto, “Characterization of [3H]CHIBA-1001 binding to α7 nicotinic acetylcholine receptors in the brain from rat, monkey, and human,” Brain Research, vol. 1348, no. C, pp. 200–208, 2010. View at Publisher · View at Google Scholar
  114. J. Toyohara, M. Sakata, J. Wu et al., “Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping α7 nicotinic receptors by positron emission tomography,” Annals of Nuclear Medicine, vol. 23, no. 3, pp. 301–309, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Sakata, J. Wu, J. Toyohara et al., “Biodistribution and radiation dosimetry of the α7 nicotinic acetylcholine receptor ligand [11C]CHIBA-1001 in humans,” Nuclear Medicine and Biology. In press. View at Publisher · View at Google Scholar
  116. J. Wu, J. Toyohara, Y. Tanibuchi et al., “Pharmacological characterization of [125I]CHIBA-1006 binding, a new radioligand for α7 nicotinic acetylcholine receptors, to rat brain membranes,” Brain Research, vol. 1360, no. C, pp. 130–137, 2010. View at Publisher · View at Google Scholar